Related Experiment Video

Updated: Apr 3, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

6.3K

Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report

Diane K Wherrett1, Jane L Chiang2, Alan M Delamater3

  • 1Department of Pediatrics, University of Toronto, Toronto, Canada.

Diabetes Care
|September 26, 2015
PubMed

Insights

Type 1 diabetes presents more aggressively in children than adults, necessitating distinct therapeutic approaches. This report outlines key differences and proposes strategies for developing pediatric type 1 diabetes treatments.

Area of Science:

  • Pediatric Endocrinology
  • Immunology
  • Translational Medicine

Background:

  • Type 1 diabetes (T1D) exhibits distinct clinical and pathophysiological characteristics in pediatric versus adult populations.
  • These differences suggest that T1D therapies effective in adults may have varying efficacy in children.
  • Current research and therapeutic development often do not adequately account for these pediatric-specific nuances.

Purpose of the Study:

  • To characterize the fundamental differences in type 1 diabetes between children and adults.
  • To propose an optimized approach for the development and regulatory pathways of T1D-modifying therapies in pediatric populations.
  • To facilitate the translation of scientific advancements into clinical care for children with T1D.

Main Methods:

  • Consensus report development involving key stakeholders.
  • Review and synthesis of emerging data on pediatric versus adult T1D.
  • Analysis of current developmental and regulatory frameworks for T1D therapies.

Main Results:

  • Type 1 diabetes in children is characterized by more aggressive disease progression and unique pathophysiological mechanisms compared to adults.
  • Significant differences exist in the clinical course and treatment response between pediatric and adult T1D patients.
  • Existing developmental and regulatory pathways may not be fully optimized for pediatric T1D therapies.

Conclusions:

  • Recognizing and addressing the distinct nature of pediatric type 1 diabetes is crucial for effective treatment development.
  • A tailored approach to therapy development and regulation is needed to accelerate the translation of novel T1D interventions for children.
  • Collaboration among industry, academia, patient advocacy, and regulatory bodies is essential to advance pediatric T1D care.

More Related Videos

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-1906:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

3.4K
Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells06:27

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

17.5K

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
6.0K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.6K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.4K
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.8K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
335